US 12,458,808 B2
Therapy systems with quantified biomarker targeting, including for epilepsy treatment, and associated systems and methods
Kent Leyde, Redmond, WA (US); Brian Lundstrom, Redmond, WA (US); Gregory Worrell, Rochester, MN (US); Squire Matthew Stead, Bozeman, MT (US); and Warren Douglas Sheffield, Redmond, WA (US)
Assigned to Cadence Neuroscience, Inc., Redmond, WA (US); and Mayo Foundation for Medical Education and Research, Rochester, MN (US)
Filed by Cadence Neuroscience, Inc., Redmond, WA (US)
Filed on Apr. 26, 2021, as Appl. No. 17/240,746.
Claims priority of provisional application 63/016,257, filed on Apr. 27, 2020.
Prior Publication US 2021/0346709 A1, Nov. 11, 2021
Int. Cl. A61N 2/00 (2006.01); A61B 5/00 (2006.01); A61B 5/293 (2021.01); A61B 5/37 (2021.01); A61N 1/36 (2006.01); A61N 1/372 (2006.01)
CPC A61N 2/002 (2013.01) [A61N 1/36064 (2013.01); A61N 1/36135 (2013.01); A61N 1/36157 (2013.01); A61N 1/36171 (2013.01); A61N 1/36175 (2013.01); A61N 2/006 (2013.01)] 13 Claims
OG exemplary drawing
 
1. A system for treating epilepsy in a patient, the system comprising:
at least one therapy signal delivery electrode configured to deliver an electrical therapy signal to a brain of the patient;
at least one sensing electrode configured to detect one or more indications of an interictal EEG biomarker in the brain of the patient; and
one or more non-transitory computer-readable media storing computer-executable instruction that, when executed by one or more processors, cause the one or more processors to perform operations comprising:
receiving, via the at least one sensing electrode, multiple indications of the interictal EEG biomarker over a time period,
processing the multiple indications to produce a processed biomarker, wherein the processed biomarker includes a spectral power ratio corresponding to the multiple indications; and
using the processed biomarker to identify:
at least one target location at the patient's brain to receive, via the at least one therapy signal delivery electrode, the electrical therapy signal to reduce or eliminate epileptic activity in the patient, and
at least one additional signal delivery parameter in accordance with which the electrical therapy signal is to be delivered.